Tirzepatide 5mg

Tirzepatide 5mg is a dual agonist peptide developed for advanced metabolic research, particularly in studies related to glucose regulation, insulin sensitivity, and body weight management. As a novel investigational compound, Tirzepatide has garnered scientific interest due to its combined GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor activity, making it a unique candidate for obesity, diabetes, and metabolic syndrome research models. Its multi-targeted mechanism has shown promise in improving metabolic parameters beyond what single-pathway agents can achieve.

How it works
Tirzepatide works by simultaneously activating GIP and GLP-1 receptors, two key hormones involved in insulin secretion and appetite regulation. This dual action enhances glucose-dependent insulin release, suppresses glucagon production, and promotes satiety, contributing to reduced food intake and improved glycemic control. Preclinical studies also indicate enhanced lipid metabolism and weight reduction, making Tirzepatide a significant subject of interest for advanced metabolic research.

Key benefits of Tirzepatide 5mg:

• Supports glucose metabolism regulation
• Enhances insulin sensitivity and secretion
• Promotes appetite suppression and satiety
• Studied for weight reduction effects
• Targets both GIP and GLP-1 receptors
• Investigated for metabolic syndrome and obesity models

Usage and safety:

• Peptide Name: Tirzepatide
• Quantity: 5mg
• Purity: ≥ 98%
• Form: Lyophilized powder
• Use: For laboratory research only. Not for human consumption.

Tirzepatide 5mg is a dual-agonist research peptide that mimics both GIP and GLP-1 activity to support insulin regulation, appetite control, and body weight management in advanced metabolic studies.

Disclaimer: This product is intended for research purposes only. Not for human or veterinary use.